Printer Friendly

AMERICAN BIOGENETIC SCIENCES SIGNS LICENSE AGREEMENT WITH YAMANOUCHI PHARMACEUTICAL

 AMERICAN BIOGENETIC SCIENCES SIGNS
 LICENSE AGREEMENT WITH YAMANOUCHI PHARMACEUTICAL
 NOTRE DAME, Ind., Jan. 27 /PRNewswire/ -- American Biogenetic Sciences, Inc. (NASDAQ: MABXA) announced today that it has signed an exclusive 15 year license agreement with Yamanouchi Pharmaceutical Co., Ltd., where Yamanouchi will market test kits containing American Biogenetic Sciences, Inc.'s (ABS) monoclonal antibody, 45-J, in Japan and Taiwan.
 ABS retains all manufacturing rights for the supply of the antibody.
 Under terms of the agreement, Yamanouchi will make an initial payment of $1,000,000 to ABS, and ABS will receive royalty payments on all sales of the test kits which contain antibody 45-J.
 Antibody 45-J, which is fibrinogen-specific, is intended to be used as an in vitro diagnostic test for assessing cardiovascular risk. Fibrinogen is gaining increasing recognition as a major independent risk factor for cardiovascular disease. Several population-based studies have found that elevated levels of fibrinogen eclipse cholesterol as a predictor of future cardiovascular events such as heart attacks and strokes.
 Yamanouchi Pharmaceutical will market the ABS fibrinogen test to the diagnostic industry. The antibody will be included in automated blood test systems and administered along with routine blood tests.
 "Yamanouchi is an ideal partner for ABS," said Henry L. Nordhoff, president of ABS. "They are a major force in the Japanese market and a growing presence in the rest of Asia."
 Yamanouchi Pharmaceutical Co., Ltd. is one of Japan's leading pharmaceutical companies. The company has developed and sells a wide range of ethical pharmaceuticals, including drugs for cardiovascular, respiratory, gastrointestinal and central nervous system disorders and anticancer agents.
 ABS is a biopharmaceutical company which conducts research at the University of Notre Dame, Notre Dame, Ind. and Trinity College, Dublin, Ireland, to develop and commercialize monoclonal antibody-based products for diagnosing, preventing and treating cardiovascular disease. The company is also developing a test for the diagnosis of Alzheimer's disease. These antibodies are produced from the company's proprietary antigen-minimized mouse colony. The company is also developing a recombinant vaccine for Hepatitis A.
 -0- 1/27/92 R
 /CONTACT: Henry L. Nordhoff, president, or Fran Giambanco, vice president-administration, 516-789-2600, both of American Biogenetic Sciences; or Bonnie Sterling of Noonan/Russo Communications, 212-979-9180, for American Biogenetic Sciences/
 (MABXA) CO: American Biogenetic Sciences, Inc.; Yamanouchi
 Pharmaceutical Co., Ltd. ST: New York IN: MTC SU: LIC


JT-OS -- NY062R -- 3762 01/27/92 12:43 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 27, 1992
Words:390
Previous Article:CHRYSLER CORPORATION ORDERS AND INSTALLS A CRAY Y-MP 8I SYSTEM
Next Article:UNOCAL ANNOUNCES EARNINGS
Topics:


Related Articles
AMERICAN BIOGENETIC SCIENCES FIBRINOGEN ANTIBODY PATENT NO. 5,091,512 ISSUED
AMERICAN BIOGENETIC SCIENCES RECEIVES $15.5 MILLION FROM 100 PERCENT EXERCISE OF WARRANTS
AMERICAN BIOGENETIC SCIENCES SENDS LETTER TO SHAREHOLDERS
GENETICS INSTITUTE AND YAMANOUCHI FORM EUROPEAN PARTNERSHIP
DAVID L. NEER APPOINTED SENIOR VICE PRESIDENT - BUSINESS DEVELOPMENT, AMERICAN BIOGENETIC SCIENCES, INC.
CELLEGY ANNOUNCES EUROPEAN RESEARCH AGREEMENT
OXFORD MOLECULAR GROUP ANNOUNCES COLLABORATIVE RESEARCH AGREEMENT WITH YAMANOUCHI PHARMACEUTICAL
AMERICAN BIOGENETIC SCIENCES, INC. OBTAINS LICENSE FROM THE BRITISH MEDICAL RESEARCH COUNCIL TO HUMANIZE MONOCLONAL ANTIBODIES
YAMANOUCHI SIGNS 5-YEAR SUBSCRIPTION PACT WITH CELERA.
Yamanouchi Pharma America Receives FDA Approvable Letter for Vesicare(R) (solifenacin succinate) for Overactive Bladder; Yamanouchi Pharma America...

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters